Recent News

• 03.31.2025 - The Future of Psychedelics: Why Next-Generation Molecules Will Win [Microdose]
• 03.31.2025 - Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024
• 03.17.2025 - Enveric Biosciences Participating in BIO-Europe Spring®
• 03.06.2025 - Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark
• 02.27.2025 - Enveric Biosciences CEO Issues Letter to Shareholders
• 02.26.2025 - Enveric Biosciences’ Patent For Non-Hallucinogenic Psychedelic Compounds [Microdose]
• 02.26.2025 - EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD [Benzinga]
• 02.25.2025 - Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent
• 02.04.2025 - A New Horizon in Joint Disease Treatment: Enveric Biosciences and Restoration Biologics Forge Licensing Agreements [Microdose]
• 02.04.2025 - Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease [Benzinga]

Recent Filings

• 03.28.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.24.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.06.2025 - 8-K Current report
• 02.26.2025 - EX-99.1 EX-99.1
• 02.26.2025 - 8-K Current report
• 02.05.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors